Assuming Nader and crew has submitted the data for an EUA (wasn't NP referring to 180 parts to it - hope they put some good people on its completion), NP should have someone contact Malaysia's version of the FDA.
Two reasons:
*Some of Malaysia's hospitals had expressed interest (referenced by Dr. Nicolas)
*To spread out any attempts to "de-rail" Cytodyn's out-of-country's efforts. Along with feelers to Brazil, India, possibly Hungary, and more, starting to awaken to leronlimab, it will be harder to cover all the bases.
Also, Looks to me that there are "a lot of balls in the air." It's probably time for NP to delegate, allocate, oversee and drive this thing. He doesn't have to try and juggle it all and learn several different languages (LOL). And remembering Maboob (or whatever his name) getting the right people is a challenge.
Market Data 
Markets 
AI
